



Public Health
England



TARGET

A modified McNulty-Zelen design randomised controlled trial to evaluate the TARGET Antibiotics toolkit (Treat Antibiotics Responsibly, Guidance, Education, Tools) and its implementation

By Leah Jones, Research Assistant, Primary Care Unit – Public Health England

Public Health England

Dr Cliodna McNulty
Leah Ffion Jones
Meredith K.D. Hawking
Rebecca Owens
Dr Donna Lecky

Institute of Primary Care & Public Health, Cardiff University School of Medicine,

Dr Nick Francis, General Practitioner
Dr Micaela Gal



Nuffield Department of Primary Care Health Sciences, University of Oxford,

Dr Chris Butler, General Practitioner



Gloucester Royal Hospital


Dr Philippa Moore,
Consultant Medical
Microbiologist

Gloucestershire
Hospitals
NHS
NHS Foundation Trust



Background

What is the TARGET Antibiotics Toolkit?



TARGET Antibiotics Toolkit

To access the Antibiotic Resistance in Primary Care elearning module, please [go here](#).

What is TARGET?

TARGET stands for: Treat Antibiotics Responsibly, Guidance, Education, Tools

The TARGET Antibiotics Toolkit aims to help influence prescribers' and patients' personal attitudes, social norms and perceived barriers to optimal antibiotic prescribing. It includes a range of resources that can each be used to support prescribers' and patients' responsible antibiotic use, helping to fulfil CPD and revalidation requirements.

Who is it for, and how can it be used?

The TARGET Antibiotics Toolkit is designed to be used by the whole primary care team within the GP practice or out of hours setting. These resources can be used flexibly, either as standalone materials or as part of an integrated package. We do recommend that ALL resources are used if this is feasible.

Using the resources in the TARGET Antibiotics Toolkit will enable primary care organisations to demonstrate compliance with the Health and Social Care Act 2008: Code of Practice on the prevention and control of infections and related guidance. The Toolkit also supports recommendations made in the recent NICE guideline: [Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use](#) published August 2015 and is linked within the guideline.

The Toolkit includes:

Background information about TARGET	+
Resources for commissioners	+
Leaflets to share with patients	+
Audit Toolkits and action planning	+
National Antibiotic Management Guidance	+
Training resources	+
Resources for clinical and waiting areas	+
Self assessment checklist	+



TARGET






RCGP Royal College of General Practitioners Public Health England

TARGET Antibiotics

"There are few public health issues of potentially greater importance for society than antibiotic resistance"

2013 GAO Prof Dame Sally Davies



TARGET solution: Shared Patient Information

All systems can be personalised and used in a variety of ways.

Read code: Delap2CAK, Lemt2CE

www.rcgp.org.uk/TARGETantibiotics

TARGET acute cough: PHE Antibiotic Management Guidance

ILLNESS	CONNECTIONS	DRUG	DOSE
Acute cough, bronchitis, COPD, LRTI	<ul style="list-style-type: none"> Antibiotic use should be reserved for cases of bacterial infection. Consider Tetracycline or doxycycline with a 14-day course. Consider amoxicillin or amoxicillin/clavulanic acid with a 7-day course. Consider trimethoprim and cotrimoxazole with a 7-day course. Consider macrolides if a 14-day course is preferred. Consider nitroimidazole if a 5-day course is preferred. Consider cephalosporins if a 7-day course is preferred. Consider penicillins if a 7-day course is preferred. Consider fluoroquinolones if a 5-day course is preferred. 	Tetracycline or doxycycline	200mg or 100mg

Available via PHE RCGP website with full rationale & references

www.rcgp.org.uk/TARGETantibiotics

TARGET: Resources for clinical and waiting areas

Posters for Display

Videos for patient waiting areas

www.rcgp.org.uk/TARGETantibiotics

Acute cough

www.rcgp.org.uk/TARGETantibiotics

Public Health England



Aims and objectives



- ❖ To evaluate the TARGET workshop using an RCT design
- ❖ Does the addition of a face to face one hour TARGET workshop given by local providers result in more appropriate antibiotic prescriptions compared to controls with usual local AMS support?



Methods

- ❖ Modified McNulty-Zelen design:
 - ❖ Practices did not know they were in a trial
 - ❖ Consent given by CCG AMS lead
 - ❖ Practices stratified by antibiotic use and randomised
 - ❖ Practices able to refuse any part of the intervention
 - ❖ Practices in the same building randomised together



Methods



152 practices from 4 CCGs in England

77 intervention practices

75 control practices

40 accepted TARGET workshops

Received usual CCG support

37 declined

TOTAL attending workshops = 318 GP staff


(166 GPs, 51 Nurses, 101 Other)



Methods



40 Workshop dates and data time frames






Workshop immediate feedback (N = 269)

The workshop helped them to understand:

**Why responsible antimicrobial
prescribing was an important
issue**

**How they could optimise their
antimicrobial prescribing**





Antibiotic data analysis



- ❖ Data from CIDSC IM&T department for 32 months January 2013 – July 2015
- ❖ **Outcome variable:** number of antibiotic or antibiotic group items prescribed each month in each GP practice
- ❖ **Factors included in model:** calendar month, GP prescribing rate pre 2013, GP list size, unplanned workshop, other interventions (QP/CMO letter post 04/15)



Results

Estimated prescribing rate ratio (PRR) comparing all intervention practices compared to controls from Intention To Treat and CACE analyses.

	Analysis			
	Intention to treat		CACE (Complier-Average Causal Effect)	
	PRR (95% CI)	P	PRR (CI)	P
All antibacterials	0.973 (0.945 to 1.001)	0.06	0.939 (0.883 to 0.998)	0.04
Amoxicillin	0.956 (0.920 to 0.994)	0.02	0.924 (0.839 to 1.017)	0.11
Co-Amoxiclav	0.969 (0.891 to 1.054)	0.46	0.945 (0.778 to 1.148)	0.57
Trimethoprim	0.944 (0.898 to 0.993)	0.03	0.890 (0.805 to 0.984)	0.02
Nitrofurantoin	1.071 (0.997 to 1.150)	0.06	1.116 (0.964 to 1.293)	0.14
Pivmecillinam	1.611 (0.852 to 3.046)	0.14	model not converging	



Results



Total antibacterial prescribing

CACE analysis indicated total antibacterials significantly decreased in intervention

	Analysis			
	Intention to treat		CACE (Complier-Average Causal Effect)	
	PRR (95% CI)	P	PRR (CI)	P
All antibacterials	0.973 (0.945 to 1.001) 2.7%	0.06	0.939 (0.883 to 0.998) 6.1%	0.04



Results

Amoxicillin and Ampicillin



Significant reduction in Amoxicillin/ampicillin in workshop group

	Analysis			
	Intention to treat		CACE (Complier-Average Causal Effect)	
	PRR (95% CI)	P	PRR (CI)	P
Amoxicillin	0.956 (0.920 to 0.994) 4.4%	0.02	0.924 (0.839 to 1.017) 7.6%	0.11



Results Nitrofurantoin, Trimethoprim and Pivmecillinam TARGET



Significant reduction in Trimethoprim for the workshop group

Non-significant increase in mecillinam and Nitrofurantoin in workshop group

	Analysis			
	Intention to treat		CACE (Complier-Average Causal Effect)	
	PRR (95% CI)	P	PRR (CI)	P
Trimethoprim	0.944 (0.898 to 0.993) 5.6%	0.03	0.890 (0.805 to 0.984) 11%	0.02
Nitrofurantoin	1.071 (0.997 to 1.150) 7.1%	0.06	1.116 (0.964 to 1.293) 11.6%	0.14
Pivmecillinam	1.611 (0.852 to 3.046) 61%	0.14	model not converging	



Results

Co-amoxiclav



Non-significant decrease in Co-amoxiclav in workshop group

	Analysis			
	Intention to treat		CACE (Complier-Average Causal Effect)	
	PRR (95% CI)	P	PRR (CI)	P
Co-Amoxiclav	0.969 (0.891 to 1.054) 3.1%	0.46	0.945 (0.778 to 1.148) 5.5%	0.57



Conclusions



Workshops led to a significant:

- Decrease in amoxicillin and ampicillin
- Decrease in overall prescribing in the CACE analysis
- Decrease in trimethoprim



Public Health
England

www.RCGP.org.uk/TARGETAntibiotics



TARGET

Acknowledgements

All of the GPs and stakeholders that took part, Marie-Jet Bekkers, Graham Tanner, Philippa Moore, Alison West, Anita Sharma, Tariq Sharif, Ivor Cartmill, Adam Simon, Thomas Daines, Sue Carter, Paul Clarke, Jen Whibley, Julie Sadler, Gloria Omisakin, Sarah Clarke and Paul Wilson.